Explore comprehensive CMO services offered by ST Phi Therapeutics, supporting end-to-end Drug Development and Manufacturing. ST Phi Therapeutics enables faster, compliant, and scalable pharma innovation tailored to your needs.
Country: China
Description: ST Phi is a China‑based cell‑therapy biotech that develops “off‑the‑shelf” allogeneic T‑cell therapies under its proprietary CNK-UT platform for cancer, autoimmune and infectious diseases. They hold a U.S. patent (issued in 2025) for “Universal T cells and the method of use thereof,” which underlies their universal donor‑derived cell therapy approach. ST Phi operates a GMP‑compliant, industrial‑scale manufacturing facility (in Hangzhou, China) approved by the national regulator for Phase‑1 clinical trials, enabling scalable production of CNK‑UT cell therapies.
